Some comeback stocks need investors to believe in a miracle. This one just needs more people in seats, better film volume, and studios that remember theaters still matter. The latest quarter showed that the model has more operating leverage than the market gives it credit for, and the 2026 movie slate gives the recovery story a much cleaner setup.
IPO Watch (Sponsored)
Bloomberg is calling Elon Musk's upcoming SpaceX IPO "the biggest listing of ALL TIME."
But here's the thing - most investors will be locked out until AFTER it goes public.
Not you.
I've found a 'backdoor' that lets everyday Americans grab a pre-IPO stake in SpaceX right now.
Click Here for the FREE "SpaceX" Ticker
What Just Happened
The latest quarter was much stronger
Cinemark Holdings, Inc. (NYSE: CNK) reported first-quarter 2026 revenue of about $643 million, up 19% year over year. Adjusted EBITDA jumped 143% to roughly $88 million, and adjusted EBITDA margin expanded by 710 basis points to 13.8%. That is the important part. Cinemark is proving that when attendance and box office improve, a lot of the upside flows through the model quickly.
The loss was smaller than expected
Cinemark still posted a loss per share in Q1, but it was better than the market expected. EPS came in at negative $0.06 versus forecasts for negative $0.13. That matters because theaters are still in recovery mode, and narrowing losses while revenue and EBITDA improve is a good signal.
Estimates are moving up
Zacks upgraded Cinemark to a Rank #1 Strong Buy in May, driven by upward earnings estimate revisions. That is one of the cleaner near-term signals for the stock. If analysts are moving numbers higher while the film slate is getting better, the market has a reason to revisit the story.
Why The Business Still Matters
Theaters are not dead
The lazy take is that streaming killed theaters. The better take is that theaters became more dependent on consistent film supply. When the slate is thin, theaters struggle. When studios release the right mix of franchise films, family titles, horror, action, and mid-budget winners, theaters still pull people out of the house.
Cinemark’s Q1 results support that. The company benefited from stronger attendance, better concessions, and operating leverage. It is not back to the old normal in every respect, but the model is clearly not broken.
Concessions still carry real power
Cinemark’s results also show why theaters love higher attendance. Ticket revenue matters, but concession spending is where a lot of the profit magic happens. Management credited record concessions and stronger box-office performance as part of the reason EBITDA margin expanded so sharply in Q1.
The 2026 slate looks useful
The upcoming film calendar is one of the biggest reasons this story has life. The 2026 slate includes major releases like The Mandalorian & Grogu, Toy Story 5, Spider-Man: Brand New Day, and Avengers: Doomsday.
A stronger and more balanced slate gives Cinemark a better shot at sustained traffic instead of relying on a handful of isolated hits.
How do you typically handle a stock that's been in your portfolio for 3+ years but hasn't performed?
Innovation Focus (Sponsored)
Time magazine recently named this lab "the most disruptive company in the world."
It's not SpaceX or OpenAI. In fact, its annualized revenues have already surpassed both of these firms. And this 60-year Wall Street legend believes it's gearing up for a watershed product launch that could send its sales soaring even higher starting June 16.
Click here to learn how you can access a "pre-IPO backdoor" into this firm for just $40 a share.
*This ad is sent on behalf of Chaikin Analytics, 201 King Of Prussia Rd., Suite 650, Radnor, PA 19087. If you would like to optout from receiving offers from Chaikin Analytics please click here.
Why The Stock Has A Case
The recovery is showing up in the numbers
Cinemark’s Q1 was not just better sentiment. It was better revenue, better EBITDA, better margins, and a smaller loss than expected. That gives the bull case more weight than simply saying theaters are due for a comeback.
Studio behavior may be turning more favorable
Benchmark previously argued that the Warner Bros. Discovery sale process could benefit theater exhibitors if the eventual buyer supports stronger film volume, steadier slate output, and traditional theatrical windows.
That matters. Cinemark’s recovery depends not only on consumer demand, but also on studios giving theaters enough product to work with.
The balance sheet story is improving
Fitch upgraded Cinemark’s credit rating in late 2025, citing improved operating and financial performance, and expected leverage to fall below 3x over the following 12 to 18 months.
That is important because theaters carried real financial risk coming out of the pandemic. A cleaner credit profile gives Cinemark more room to invest, buy back shares, and ride the slate recovery.
Management is buying back stock
Cinemark has also been active with share repurchases. Buybacks are not a reason to own the stock by themselves, but they help when the business is improving and the valuation still looks reasonable. They also signal management sees value in the stock.
Elite Trade Club Insider
$100 Million More Just Went Into One Defensive Stock
A major holder bought another $101.8 million worth of shares across three straight sessions in a defensive services company still down about 14% over the past year, while a biotech CEO bought just over $1.0 million with the stock still far below its 52-week high.
Most of you see the tip of the iceberg here. Our Elite Trade Club Insider readers will see where conviction is showing up in weakness and how to take advantage of it.
You’re reading the free version. Here’s what we held back.
Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.
A subscription gets you:
The insider buys, options bets, and dark pool moves the free edition can't show you. Unlocked every weekday.
A Sunday Deep Dive that tells you where to look before Monday's bell rings.
The Friday Smart Money Brief: who bought, who sold, where the big options bets landed, and where institutions are hiding volume. Three data layers. One email.
A Monthly Insider Scorecard so you always know whether smart money is buying or selling the market.
Every past Insider edition, unlocked, on elitetrade.club. Go back and see what you missed.
$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.
What Has To Go Right
The film slate needs to deliver
This is the biggest variable. Cinemark does not control Hollywood’s release calendar, but it depends heavily on it. The company needs 2026 releases to translate into actual box-office dollars, not just good trailer buzz. If the slate lands, Cinemark’s operating leverage becomes a major advantage.
Concession trends need to stay strong
Higher attendance helps, but concession per caps and premium-format engagement are crucial. If consumers keep spending once they enter the theater, Cinemark’s margin recovery has more room.
Estimate revisions need to continue
The Zacks upgrade is useful because it reflects improving earnings expectations. The next stage is continued upward revisions after stronger quarters. That is what turns a recovery stock into a sustained winner.
Learn This First (Sponsored)
Most option books teach theory.
This one shows you the trades.
Step-by-step examples. Real setups. The exact moves a 50-year market veteran uses to keep things simple and keep his account protected.
You can follow along in your own brokerage account. Or just read it for education.
Either way, it's free today (normally $29.97).
Get your copy now.
What Could Trip It Up
A weak box office can break the momentum fast
This is still the main risk. A few disappointing releases, weaker-than-expected attendance, or another uneven slate can hit Cinemark quickly. Theaters have leverage in both directions.
Streaming pressure has not disappeared
Streaming did not kill theaters, but it still changes consumer behavior. If studios shorten windows again or push more premium releases directly to platforms, Cinemark’s recovery case gets weaker.
The stock is not deeply hidden anymore
CNK has a Buy consensus and a Benchmark target of $35, but the market already knows the slate is improving. The stock can still work, but it needs continued evidence in revenue, EBITDA, and attendance.
What I’d Watch Next
The first thing to watch is summer box office momentum. Cinemark needs the bigger 2026 releases to pull broad audiences, not just niche fans. The second is adjusted EBITDA margin, because Q1 showed strong operating leverage.
The third is concession strength, since that is where better attendance becomes better profit. The fourth is estimate revisions. If analysts keep raising numbers, the stock’s recovery case gets much stronger.
My Take
Buy at current levels. Cinemark has a cleaner setup than it has had in years: Q1 revenue grew 19%, adjusted EBITDA more than doubled, margins expanded sharply, estimates are moving higher, and the 2026 film slate looks much stronger. The stock is not risk-free, but the risk-reward now favors owning it before the full slate recovery is reflected in earnings.
The key risk is box-office volatility. Cinemark needs studios to deliver consistent releases and audiences to show up. If the 2026 slate disappoints, the operating leverage that helps the stock on the way up works against it on the way down.
Action Recap
🎬 Looking to buy? Buy at current levels while estimates are rising and the 2026 slate is still ahead.
🍿 Already own it? Keep holding. The Q1 margin expansion and stronger box office setup support more upside.
⚠️ Main risk to respect: A weak film slate or disappointing attendance can quickly reverse the recovery trade.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
